



MRC
Epidemiology
Unit



UNIVERSITY OF
CAMBRIDGE

Inter-Sustain Evaluation Committee,
Novo Nordisk Foundation, Copenhagen

9th February 2026

Dear Colleagues,

RE: Letter of Support; Daniel Witte et al entitled “Metabolic Signatures: Coupling incretin and glucagon pathways with metabolic traits in cardiometabolic disease progression”

As Head of the MRC Epidemiology Unit, University of Cambridge, I write to confirm our strong support for Daniel Witte’s application as it aligns well with our strategic aim of advancing precision prevention strategies for type 2 diabetes and related cardiometabolic complications.

We are happy to commit to:

Data Access and Collaboration. We will provide access to the Fenland Study data (n = 12,435 participants) and support harmonization of data between the Fenland Study, ADDITION-PRO, and UK Biobank for validation purposes.

Methodological Mentorship. We will offer guidance in advanced epidemiological methods to PhD students and Postdocs working in the analysis team on techniques including causal inference and Mendelian randomization, to strengthen the project’s analytical framework.

Scientific Exchange and Infrastructure. We will facilitate regular scientific exchange through joint meetings and provide expertise in integrating genetic, metabolomic and phenotypic data for precision epidemiology.

We look forward to collaborating on this project and contributing to its success. Please do not hesitate to contact us for further information.

Yours sincerely,

Professor Nick Wareham FMedSci FRCP FFPHM

PI- Fenland Study

Director, Medical Research Council Epidemiology Unit and Co-Director, Institute of Metabolic Science

T: +44 (0)1223 330315

E: nick.wareham@mrc-epid.cam.ac.uk

Medical Research Council Epidemiology Unit

University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science,
Cambridge Biomedical Campus, Cambridge CB2 0QQ